Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
about
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesGuidelines for the management of myeloproliferative neoplasmsHematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age GroupsEmerging drugs for myelofibrosis.Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisImpact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisPrimary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.Advances in myelofibrosis: a clinical case approach.Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms.Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Current Challenges in Stem Cell Transplantation in Myelofibrosis.Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?Treatment of Myelofibrosis: Old and New Strategies.Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation.Emerging therapeutic options for myelofibrosis: a Canadian perspective.Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantationAllogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.
P2860
Q26750696-36E4F684-AE3B-4721-942F-B4E885BC96C1Q26752940-9F8B7F81-F6BB-4419-8A54-103C4AFDDC5CQ26778326-7D6898BE-2542-4760-8405-8D0ED6703178Q26786893-0B1E515B-CD31-4316-A506-0F991611EBEDQ33404574-A5D35FFE-B4A2-4789-9AB7-181A7D62EC58Q33419957-EFAF5364-430F-4F7A-9285-F83752B72780Q33439559-62FA1B48-01E1-46C3-A78C-2F2D6871AEAFQ34047897-389F15F3-CA41-4C57-9774-3027412E3C05Q35634902-87D9C88B-E06A-4C9A-9511-F2EF384220D0Q35735663-D1A2E473-7CA6-42CD-AF3E-98BD12DFC388Q35925091-812879F2-327B-4E72-91B6-F3FE76B723D4Q37035925-324A1E61-0C7F-459D-991A-EC73A293E413Q37212674-26185A0C-7107-403A-A2D3-6CE361CB748DQ37272164-6E575CB4-73FA-4F72-909D-624AEF019166Q37457111-F4701FFE-E1B7-4199-A3EC-0FB1D95A4948Q37548944-F75983C1-49E5-451C-A2D4-BF0A443056E2Q38046648-F2F0E3A4-5324-4E45-81FA-C10BD608594BQ38065306-7DCE3F73-D77A-4C2C-BFCF-6F871C22EF44Q38174781-5570C168-DC0E-4AEF-81D5-89E06B6E88C6Q38187674-D0E601B1-AADD-47A4-935A-581909532514Q38236642-7D45FA15-6B52-4FB1-94EE-467C5487AC9DQ38254425-39B5C69A-3E12-4E4B-934D-51EC53F48AFFQ38341625-52F89722-E8C4-4AFE-923A-CC4726EB080DQ38349213-119DE0CA-C7D7-4F2F-B3D2-77F15233C44AQ38569146-2940C249-2981-4A1C-8EF7-0240240793F9Q38570614-1453AA4B-C407-4CA7-9E46-E771D94559FCQ38667263-62060E4F-0884-4347-9CAC-19CFD0737EF0Q39349869-20A3ED3A-049C-4AEF-A80C-230214E1079DQ40086569-B0ABED4F-42DD-4494-A730-0A2EE10C9057Q41627599-E2D33745-EA8B-405F-B0E2-371FB49C0179Q42111169-5C495991-C7C3-4657-B30D-7BDAA1AAD31AQ53099028-A375F195-508C-4E76-A0EB-86363643AB3BQ55060741-D58C9A87-3FA9-4956-8FD4-CE7AC059DB03
P2860
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Allogeneic hematopoietic cell ...... in the era of JAK inhibitors.
@en
type
label
Allogeneic hematopoietic cell ...... in the era of JAK inhibitors.
@en
prefLabel
Allogeneic hematopoietic cell ...... in the era of JAK inhibitors.
@en
P2860
P1433
P1476
Allogeneic hematopoietic cell ...... in the era of JAK inhibitors.
@en
P2093
Ronald Hoffman
Vikas Gupta
P2860
P304
P356
10.1182/BLOOD-2012-05-399048
P407
P577
2012-06-14T00:00:00Z